CYP2J2 participates in atherogenesis by mediating cell proliferation, migration and foam cell formation

Li,Rui; Zhang,Yuan; Yan,Huacheng; Xiao,Hua; Ruan,Yunjun; Qiu,Jian; Shi,Lei

doi:10.3892/mmr.2016.6039

CYP2J2 participates in atherogenesis by mediating cell proliferation, migration and foam cell formation

Authors:
- Rui Li
- Yuan Zhang
- Huacheng Yan
- Hua Xiao
- Yunjun Ruan
- Jian Qiu
- Lei Shi
View Affiliations

Affiliations: Department of Cardiology, Guangzhou General Hospital of Guangzhou Military Command, Guangzhou, Guangdong 510010, P.R. China
Published online on: December 14, 2016 https://doi.org/10.3892/mmr.2016.6039
Pages: 643-648
Copyright: © Li et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Atherosclerosis (AS) is a common pathological basis for the development of various cardiovascular and cerebrovascular diseases, however, currently, no effective treatment against AS has been established. It has previously been suggested that intravascular cytochrome P450 (CYP) oxidase is involved in the pathogenesis of AS. The present study investigated the role of cytochrome P450, family 2, subfamily J, polypeptide 2 (CYP2J2), the most common subtype of CYP oxidase in the human body, in the occurrence and development of AS. CYP2J2 was overexpressed in human umbilical vein endothelial cells (HUVECs), human arterial smooth muscle cells (HASMCs), and human peripheral monocyte‑derived foam cells by lentiviral infection. The mRNA and protein levels were measured by reverse‑transcription quantitative polymerase chain reaction and western blotting, respectively. Cell proliferation and migration were determined by MTS and Transwell assays, respectively. Furthermore, lipid accumulation was detected with Oil red O staining. The concentrations of total and free cholesterol were measured using a quantitation kit. Following lentiviral infection, CYP2J2 was successfully overexpressed in HUVEC, HASMC and foam cells. CYP2J2 overexpression promoted proliferation and migration in HUVECs and suppressed these actions in HASMCs. In addition, it suppressed oxidized low‑density lipoprotein‑induced foam cell formation. In conclusion, it was hypothesized that CYP2J2 may have a protective role in AS, as proliferation of HASMCs and the formation of foam cells are notable characteristics of AS.

View Figures

View References

1	Negi S and Anand A: Atherosclerotic coronary heart disease-epidemiology, classification and management. Cardiovasc Hematol Disord Drug Targets. 10:257–261. 2010. View Article : Google Scholar : PubMed/NCBI
2	Weber C and Noels H: Atherosclerosis: Current pathogenesis and therapeutic options. Nat Med. 17:1410–1422. 2011. View Article : Google Scholar : PubMed/NCBI
3	Chen Z and Xu H: Anti-inflammatory and immunomodulatory mechanism of tanshinone IIA for atherosclerosis. Evid Based Complement Alternat Med. 2014:2679762014. View Article : Google Scholar : PubMed/NCBI
4	Athirakul K, Bradbury JA, Graves JP, DeGraff LM, Ma J, Zhao Y, Couse JF, Quigley R, Harder DR, Zhao X, et al: Increased blood pressure in mice lacking cytochrome P450 2J5. FASEB J. 22:4096–4108. 2008. View Article : Google Scholar : PubMed/NCBI
5	Bodiga S, Zhang R, Jacobs DE, Larsen BT, Tampo A, Manthati VL, Kwok WM, Zeldin DC, Falck JR, Gutterman DD, et al: Protective actions of epoxyeicosatrienoic acid: Dual targeting of cardiovascular PI3K and KATP channels. J Mol Cell Cardiol. 46:978–988. 2009. View Article : Google Scholar : PubMed/NCBI
6	Lee CR, Imig JD, Edin ML, Foley J, DeGraff LM, Bradbury JA, Graves JP, Lih FB, Clark J, Myers P, et al: Endothelial expression of human cytochrome P450 epoxygenases lowers blood pressure and attenuates hypertension-induced renal injury in mice. FASEB J. 24:3770–3781. 2010. View Article : Google Scholar : PubMed/NCBI
7	Node K, Huo Y, Ruan X, Yang B, Spiecker M, Ley K, Zeldin DC and Liao JK: Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids. Science. 285:1276–1279. 1999. View Article : Google Scholar : PubMed/NCBI
8	Node K, Ruan XL, Dai J, Yang SX, Graham L, Zeldin DC and Liao JK: Activation of Galpha s mediates induction of tissue-type plasminogen activator gene transcription by epoxyeicosatrienoic acids. J Biol Chem. 276:15983–15989. 2001. View Article : Google Scholar : PubMed/NCBI
9	Wang Y, Wei X, Xiao X, Hui R, Card JW, Carey MA, Wang DW and Zeldin DC: Arachidonic acid epoxygenase metabolites stimulate endothelial cell growth and angiogenesis via mitogen-activated protein kinase and phosphatidylinositol 3-kinase/Akt signaling pathways. J Pharmacol Exp Ther. 314:522–532. 2005. View Article : Google Scholar : PubMed/NCBI
10	Xiao B, Li X, Yan J, Yu X, Yang G, Xiao X, Voltz JW, Zeldin DC and Wang DW: Overexpression of cytochrome P450 epoxygenases prevents development of hypertension in spontaneously hypertensive rats by enhancing atrial natriuretic peptide. J Pharmacol Exp Ther. 334:784–794. 2010. View Article : Google Scholar : PubMed/NCBI
11	Xu X, Zhang XA and Wang DW: The roles of CYP450 epoxygenases and metabolites, epoxyeicosatrienoic acids, in cardiovascular and malignant diseases. Adv Drug Deliv Rev. 63:597–609. 2011. View Article : Google Scholar : PubMed/NCBI
12	Yang S, Lin L, Chen JX, Lee CR, Seubert JM, Wang Y, Wang H, Chao ZR, Tao DD, Gong JP, et al: Cytochrome P-450 epoxygenases protect endothelial cells from apoptosis induced by tumor necrosis factor-alpha via MAPK and PI3K/Akt signaling pathways. Am J Physiol Heart Circ Physiol. 293:H142–H151. 2007. View Article : Google Scholar : PubMed/NCBI
13	Zufferey R, Dull T, Mandel RJ, Bukovsky A, Quiroz D, Naldini L and Trono D: Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery. J Virol. 72:9873–9880. 1998.PubMed/NCBI
14	Dull T, Zufferey R, Kelly M, Mandel RJ, Nguyen M, Trono D and Naldini L: A third-generation lentivirus vector with a conditional packaging system. J Virol. 72:8463–8471. 1998.PubMed/NCBI
15	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
16	Li Q, Zhao JH, Ma PJ, Su LL, Tao SB and Ji SB: Association of CYP2J2 gene polymorphisms with ischemic stroke. Int J Clin Exp Med. 8:8163–8167. 2015.PubMed/NCBI
17	Kumar AS Arun, Kumar SS, Umamaheswaran G, Kesavan R, Balachandar J and Adithan C: Association of CYP2C8, CYP2C9 and CYP2J2 gene polymorphisms with myocardial infarction in South Indian population. Pharmacol Rep. 67:97–101. 2015. View Article : Google Scholar : PubMed/NCBI
18	Lee CR, North KE, Bray MS, Couper DJ, Heiss G and Zeldin DC: CYP2J2 and CYP2C8 polymorphisms and coronary heart disease risk: The atherosclerosis risk in communities (ARIC) study. Pharmacogenet Genomics. 17:349–358. 2007. View Article : Google Scholar : PubMed/NCBI
19	Zhang S, Chen G, Li N, Dai M, Chen C, Wang P, Tang H, Hoopes SL, Zeldin DC, Wang DW and Xu X: CYP2J2 overexpression ameliorates hyperlipidemia via increased fatty acid oxidation mediated by the AMPK pathway. Obesity (Silver Spring). 23:1401–1413. 2015. View Article : Google Scholar : PubMed/NCBI
20	Yang L, Ni L, Duan Q, Wang X, Chen C, Chen S, Chaugai S, Zeldin DC, Tang JR and Wang DW: CYP epoxygenase 2J2 prevents cardiac fibrosis by suppression of transmission of pro-inflammation from cardiomyocytes to macrophages. Prostaglandins Other Lipid Mediat. 116–117, 64–75. 2015.
21	Westphal C, Spallek B, Konkel A, Marko L, Qadri F, DeGraff LM, Schubert C, Bradbury JA, Regitz-Zagrosek V, Falck JR, et al: CYP2J2 overexpression protects against arrhythmia susceptibility in cardiac hypertrophy. PLoS One. 8:e734902013. View Article : Google Scholar : PubMed/NCBI
22	Spiecker M, Darius H, Hankeln T, Soufi M, Sattler AM, Schaefer JR, Node K, Börgel J, Mügge A, Lindpaintner K, et al: Risk of coronary artery disease associated with polymorphism of the cytochrome P450 epoxygenase CYP2J2. Circulation. 110:2132–2136. 2004. View Article : Google Scholar : PubMed/NCBI
23	Zhu Q, Fu Z, Ma Y, Yang H, Huang D, Xie X, Liu F, Zheng Y and Cha E: A novel polymorphism of the CYP2J2 gene is associated with coronary artery disease in Uygur population in China. Clin Biochem. 46:1047–1054. 2013. View Article : Google Scholar : PubMed/NCBI
24	Doran AC, Meller N and McNamara CA: Role of smooth muscle cells in the initiation and early progression of atherosclerosis. Arterioscler Thromb Vasc Biol. 28:812–819. 2008. View Article : Google Scholar : PubMed/NCBI
25	Ross R: The pathogenesis of atherosclerosis: A perspective for the 1990s. Nature. 362:801–809. 1993. View Article : Google Scholar : PubMed/NCBI
26	Lu Q, Qiu TQ and Yang H: Ligustilide inhibits vascular smooth muscle cells proliferation. Eur J Pharmacol. 542:136–140. 2006. View Article : Google Scholar : PubMed/NCBI
27	Eun SY, Ko YS, Park SW, Chang KC and Kim HJ: IL-1β enhances vascular smooth muscle cell proliferation and migration via P2Y2 receptor-mediated RAGE expression and HMGB1 release. Vascul Pharmacol. 72:108–117. 2015. View Article : Google Scholar : PubMed/NCBI
28	Yu XH, Fu YC, Zhang DW, Yin K and Tang CK: Foam cells in atherosclerosis. Clin Chim Acta. 424:245–252. 2013. View Article : Google Scholar : PubMed/NCBI